A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
← catalyst calendarSponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The study was terminated due to lack of enrollment resulting from a change in the standard of care for the first-line treatment of patients with cholangiocarcinoma. There were no safety concerns that contributed to this decision.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-06-03 | actual | When the study began enrolling |
| Primary completion | 2025-07-07 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-07 | actual | The whole study's end, after follow-up |
| First posted | 2018-09-04 | actual | When this record first appeared on the registry |
| Results posted | 2026-08-11 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Unresectable Cholangiocarcinoma
- Metastatic Cholangiocarcinoma
Interventions
- Drug: Pemigatinib — also filed as INCB054828
- Drug: Gemcitabine
- Drug: Cisplatin
Primary outcomes
what the primary-completion date above is the date OFPosted documents
hosted by the registry — we link, never re-servePublications
- PMID 42223137 — linked by the registry
- PMID 32677452 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed